Research programme: dopamine transporter targeted imaging agents - Alseres

Drug Profile

Research programme: dopamine transporter targeted imaging agents - Alseres

Alternative Names: O 1505; O 1505T

Latest Information Update: 12 May 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard University
  • Developer Alseres Pharmaceuticals
  • Class Imaging agents
  • Mechanism of Action Dopamine plasma membrane transport protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 14 Sep 2007 Preclinical development is ongoing
  • 08 Jun 2007 Boston Life Sciences is now called Alseres Pharmaceuticals
  • 17 Aug 2005 Preclinical trials in Parkinson's disease and Atttention-deficit hyperactivity disorder diagnosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top